<p>Cabaletta Bio（納斯達克代碼：CABA - 獲取免費報告）預計將在 2025 年 3 月 12 日星期四市場開盤前發佈其 2025 年第四季度財報。分析師預計 Cabaletta Bio 本季度每股收益為（$0.4579）。感興趣的人士可以訪問公司即將發佈的 2025 年第四季度財報頁面，獲取關於定於 2026 年 3 月 27 日星期五上午 8:00（東部時間）電話會議的最新信息。</p>
<p>獲取 <strong>Cabaletta Bio</strong> 的提醒：</p>
<h2>Cabaletta Bio 股票上漲 5.5%</h2>
<p>納斯達克 CABA 週四開盤價為 $3.43。該股票市值為 $3.3017 億，市盈率為 -1.36，貝塔值為 3.25。Cabaletta Bio 的 52 周低點為 $0.99，52 周高點為 $3.78。該公司的 50 日移動平均價格為 $2.62，200 日移動平均價格為 $2.39。</p>
<h2>內部買賣</h2>
<p>在相關消息中，內部人士 Steve Gavel 於 1 月 21 日星期三購買了 22,170 股公司的股票，交易價格為每股平均$2.27，總價值為$50,325.90。購買後，內部人士持有 22,170 股公司股票，價值約為$50,325.90。該交易使其持股增加了∞。此次收購已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，首席執行官 Steven Nichtberger 於 1 月 21 日星期三購買了 45,000 股 Cabaletta Bio 股票，交易價格為每股平均$2.24，總價值為$100,800.00。收購完成後，首席執行官在公司持有 1,031,483 股，價值約為$2,310,521.92。該交易使其持股增加了 4.56%。此次購買的披露信息可在 SEC 文件中找到。過去三個月，內部人士共購買了 127,668 股公司股票，價值$286,211。目前，11.25% 的股票由公司內部人士持有。</p>
<h2>Cabaletta Bio 的機構交易</h2>
<p>對沖基金最近增加或減少了對該公司的持股。T. Rowe Price Investment Management Inc.在第四季度將其在 Cabaletta Bio 的持股增加了 17.9%。T. Rowe Price Investment Management Inc.目前持有 9,858,257 股公司股票，價值$21,590,000，在此期間又購買了 1,495,768 股。Adage Capital Partners GP L.L.C.在第二季度將其在 Cabaletta Bio 的持股增加了 142.9%。Adage Capital Partners GP L.L.C.目前持有 8,829,758 股公司股票，價值$13,421,000，在上個季度又購買了 5,195,285 股。Vanguard Group Inc.在第三季度將其在 Cabaletta Bio 的持股增加了 21.4%。Vanguard Group Inc.目前持有 4,190,759 股公司股票，價值$9,806,000，在此期間又收購了 740,032 股。Millennium Management LLC 在第四季度將其在 Cabaletta Bio 的持股增加了 298.5%。Millennium Management LLC 目前持有 2,736,912 股公司股票，價值$5,994,000，在上個季度又收購了 2,050,099 股。最後，Superstring Capital Management LP 在第四季度將其在 Cabaletta Bio 的持股增加了 45.9%。Superstring Capital Management LP 目前持有 2,253,550 股公司股票，價值$4,935,000，在上個季度又收購了 709,025 股。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 1 月 21 日星期三的研究報告中重新發布了對 Cabaletta Bio 股票的 “賣出（d-）” 評級。七位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Cabaletta Bio 的平均評級為 “適度買入”，共識目標價為$16.25。</p>
<p><strong>查看我們對 Cabaletta Bio 的最新股票分析</strong></p>
<h2>Cabaletta Bio 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Cabaletta Bio 是一家臨牀階段的生物技術公司，開創了用於 B 細胞介導的自身免疫疾病的嵌合自抗體受體 T 細胞（CAAR-T）療法。其專有平台工程化患者來源的 T 細胞，以選擇性地靶向和消除產生疾病驅動自抗體的致病 B 細胞，旨在保護整體免疫功能並減少非靶向毒性。</p>
<p>該公司的主要候選藥物 DSG3-CAART 正在評估用於治療天皰瘡，這是一種由針對 desmoglein 3 的自抗體引起的罕見水皰性疾病。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更喜歡的五隻股票比 Cabaletta Bio 更好</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國 1776 年再次發生</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這 4 個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Cabaletta Bio 嗎？</h2>
<p>在你考慮 Cabaletta Bio 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Cabaletta Bio 並不在名單上。</p>
<p>雖然 Cabaletta Bio 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

IBBQ

<p>Cabaletta Bio（納斯達克代碼：CABA）定於 3 月 12 日發佈 2025 年第四季度財報，分析師預計每股虧損為 0.4579 美元。該股票上漲了 5.5%，開盤價為 3.43 美元，市值為 3.3017 億美元。最近的內部交易包括首席執行官 Steven Nichtberger 和內部人士 Steve Gavel 的購買。機構投資者也增加了他們的持股，T. Rowe Price 和 Adage Capital 是其中的知名投資者。Weiss Ratings 給予了 “賣出（d-）” 評級，而共識評級仍為 “適度買入”，目標價為 16.25 美元</p>

<p>Cabaletta Bio (NASDAQ:CABA - Get Free Report) is projected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Cabaletta Bio to post earnings of ($0.4579) per share for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.</p>
<div class="lb-trans"><p>Cabaletta Bio（納斯達克代碼：CABA - 獲取免費報告）預計將在 2025 年 3 月 12 日星期四市場開盤前發佈其 2025 年第四季度財報。分析師預計 Cabaletta Bio 本季度每股收益為（$0.4579）。感興趣的人士可以訪問公司即將發佈的 2025 年第四季度財報頁面，獲取關於定於 2026 年 3 月 27 日星期五上午 8:00（東部時間）電話會議的最新信息。</p>
</div><p>Get <strong>Cabaletta Bio</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cabaletta Bio</strong> 的提醒：</p>
</div><h2>Cabaletta Bio Stock Up 5.5%</h2>
<div class="lb-trans"><h2>Cabaletta Bio 股票上漲 5.5%</h2>
</div><p>NASDAQ CABA opened at $3.43 on Thursday. The stock has a market cap of $330.17 million, a PE ratio of -1.36 and a beta of 3.25. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $3.78. The business has a 50 day moving average price of $2.62 and a two-hundred day moving average price of $2.39.</p>
<div class="lb-trans"><p>納斯達克 CABA 週四開盤價為 $3.43。該股票市值為 $3.3017 億，市盈率為 -1.36，貝塔值為 3.25。Cabaletta Bio 的 52 周低點為 $0.99，52 周高點為 $3.78。該公司的 50 日移動平均價格為 $2.62，200 日移動平均價格為 $2.39。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, insider Steve Gavel acquired 22,170 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,325.90. Following the purchase, the insider owned 22,170 shares of the company's stock, valued at approximately $50,325.90. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Nichtberger bought 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the completion of the acquisition, the chief executive officer owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. The trade was a 4.56% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 127,668 shares of company stock valued at $286,211 in the last three months. 11.25% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Steve Gavel 於 1 月 21 日星期三購買了 22,170 股公司的股票，交易價格為每股平均$2.27，總價值為$50,325.90。購買後，內部人士持有 22,170 股公司股票，價值約為$50,325.90。該交易使其持股增加了∞。此次收購已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，首席執行官 Steven Nichtberger 於 1 月 21 日星期三購買了 45,000 股 Cabaletta Bio 股票，交易價格為每股平均$2.24，總價值為$100,800.00。收購完成後，首席執行官在公司持有 1,031,483 股，價值約為$2,310,521.92。該交易使其持股增加了 4.56%。此次購買的披露信息可在 SEC 文件中找到。過去三個月，內部人士共購買了 127,668 股公司股票，價值$286,211。目前，11.25% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of Cabaletta Bio</h2>
<div class="lb-trans"><h2>Cabaletta Bio 的機構交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its position in Cabaletta Bio by 17.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company's stock worth $21,590,000 after purchasing an additional 1,495,768 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Cabaletta Bio by 142.9% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company's stock valued at $13,421,000 after buying an additional 5,195,285 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Cabaletta Bio by 21.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company's stock worth $9,806,000 after acquiring an additional 740,032 shares during the period. Millennium Management LLC boosted its position in shares of Cabaletta Bio by 298.5% during the 4th quarter. Millennium Management LLC now owns 2,736,912 shares of the company's stock valued at $5,994,000 after acquiring an additional 2,050,099 shares in the last quarter. Finally, Superstring Capital Management LP boosted its position in shares of Cabaletta Bio by 45.9% during the 4th quarter. Superstring Capital Management LP now owns 2,253,550 shares of the company's stock valued at $4,935,000 after acquiring an additional 709,025 shares in the last quarter.</p>
<div class="lb-trans"><p>對沖基金最近增加或減少了對該公司的持股。T. Rowe Price Investment Management Inc.在第四季度將其在 Cabaletta Bio 的持股增加了 17.9%。T. Rowe Price Investment Management Inc.目前持有 9,858,257 股公司股票，價值$21,590,000，在此期間又購買了 1,495,768 股。Adage Capital Partners GP L.L.C.在第二季度將其在 Cabaletta Bio 的持股增加了 142.9%。Adage Capital Partners GP L.L.C.目前持有 8,829,758 股公司股票，價值$13,421,000，在上個季度又購買了 5,195,285 股。Vanguard Group Inc.在第三季度將其在 Cabaletta Bio 的持股增加了 21.4%。Vanguard Group Inc.目前持有 4,190,759 股公司股票，價值$9,806,000，在此期間又收購了 740,032 股。Millennium Management LLC 在第四季度將其在 Cabaletta Bio 的持股增加了 298.5%。Millennium Management LLC 目前持有 2,736,912 股公司股票，價值$5,994,000，在上個季度又收購了 2,050,099 股。最後，Superstring Capital Management LP 在第四季度將其在 Cabaletta Bio 的持股增加了 45.9%。Superstring Capital Management LP 目前持有 2,253,550 股公司股票，價值$4,935,000，在上個季度又收購了 709,025 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cabaletta Bio has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $16.25.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 21 日星期三的研究報告中重新發布了對 Cabaletta Bio 股票的 “賣出（d-）” 評級。七位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Cabaletta Bio 的平均評級為 “適度買入”，共識目標價為$16.25。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Cabaletta Bio</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Cabaletta Bio 的最新股票分析</strong></p>
</div><h2>Cabaletta Bio Company Profile</h2>
<div class="lb-trans"><h2>Cabaletta Bio 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.</p>
<div class="lb-trans"><p>Cabaletta Bio 是一家臨牀階段的生物技術公司，開創了用於 B 細胞介導的自身免疫疾病的嵌合自抗體受體 T 細胞（CAAR-T）療法。其專有平台工程化患者來源的 T 細胞，以選擇性地靶向和消除產生疾病驅動自抗體的致病 B 細胞，旨在保護整體免疫功能並減少非靶向毒性。</p>
</div><p>The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.</p>
<div class="lb-trans"><p>該公司的主要候選藥物 DSG3-CAART 正在評估用於治療天皰瘡，這是一種由針對 desmoglein 3 的自抗體引起的罕見水皰性疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Cabaletta Bio</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Cabaletta Bio 更好</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國 1776 年再次發生</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這 4 個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CABA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cabaletta Bio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Cabaletta Bio 嗎？</h2>
</div><p>Before you consider Cabaletta Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cabaletta Bio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Cabaletta Bio 並不在名單上。</p>
</div><p>While Cabaletta Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cabaletta Bio 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Cabaletta Bio (CABA) 將在週四公佈季度收益報告